# Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

> **NCT06881290** · PHASE1 · RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 20 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Vunakizumab (IL-17A inhibitor)

## Key facts

- **NCT ID:** NCT06881290
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2026-11-20
- **Final completion:** 2027-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06881290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06881290, "Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06881290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*